GlassScriptPhysician profile
Gopal Chalavarya
NPI 1922093921
$40,010.64
in general payments reported to CMS, 2019-2025
29 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,252 · 2020: $262 · 2021: $885 · 2022: $2,523 · 2023: $10K · 2024: $11K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $32K · Food and Beverage: $1,405 · Travel and Lodging: $17.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $31,666.67 |
| Food and Beverage | $1,404.51 |
| Travel and Lodging | $17.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $33,833.34 | 2022-2025 | Auryon Laser System 100-120 Vac |
| Penumbra, INC. | $1,269.19 | 2019-2025 | Indigo System |
| Boston Scientific Corporation | $1,039.73 | 2019-2025 | Watchman Flx, Eluvia |
| Medtronic, INC. | $664.03 | 2021-2024 | Micra, Linq II, Tyrx |
| Abbott Laboratories | $472.23 | 2019-2025 | Cardiomems, Diamondback Peripheral |
| Janssen Pharmaceuticals, INC | $468.47 | 2019-2024 | Xarelto |
| Endologix LLC | $347.61 | 2019 | |
| Janssen Scientific Affairs, LLC | $210.09 | 2019-2020 | |
| Recor Medical INC | $194.02 | 2024 | Paradise Renal Denervation System |
| Edwards Lifesciences Corporation | $182.56 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $162.44 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $157.97 | 2019-2022 | |
| Abiomed | $156.87 | 2019 | |
| Medtronic Vascular, INC. | $148.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.95 | 2024-2025 | Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $96.54 | 2019-2025 | |
| Ekos Corporation | $96.50 | 2019 | |
| Cardiovascular Systems INC. | $80.17 | 2019-2023 | Diamondback Peripheral |
| Shockwave Medical, INC | $65.58 | 2021 | |
| Pfizer INC. | $50.69 | 2023-2024 | |
| Cook Medical LLC | $44.60 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $32.33 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $29.57 | 2023 | |
| Insulet Corporation | $23.07 | 2023 | Omnipod |
| Philips North America LLC | $19.76 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $19.72 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $15.36 | 2023 | Uptravi, Opsumit |
| Catheter Precision, INC. Fka Ra Medical Systems, INC. | $11.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gopal Chalavarya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.